```html

Vasculitic Skin Lesions

What is Vasculitic skin lesions?

Vasculitic skin lesions are skin manifestations that result from inflammation of the small‑ or medium‑sized blood vessels (vasculitis) within the dermis and subcutaneous tissue. The inflamed vessels become damaged, leak blood, or become occluded, creating a distinctive range of rashes, purpura, nodules, or ulcerations. Because the skin is easily inspected, cutaneous vasculitis often provides the first clue to an underlying systemic vasculitic disorder.

Vasculitis can be primary (the blood‑vessel inflammation is the main disease) or secondary (it occurs as a reaction to infection, medication, or another autoimmune condition). The skin lesions themselves are not contagious, but they may signal a serious internal process that requires prompt medical evaluation.

Common Causes

Various diseases and triggers can produce vasculitic skin lesions. The most frequently encountered causes include:

• IgA vasculitis (Henoch‑Schönlein purpura) – immune complex deposition most common in children.
• Leukocytoclastic (cutaneous small‑vessel) vasculitis – often drug‑induced or infection‑related.
• Granulomatosis with polyangiitis (GPA, formerly Wegener’s) – necrotizing granulomatous inflammation affecting upper airway, lungs, kidneys, and skin.
• Eosinophilic granulomatosis with polyangiitis (EGPA, Churg‑Strauss) – asthma‑associated eosinophilic vasculitis.
• Microscopic polyangiitis (MPA) – pauci‑immune small‑vessel vasculitis.
• Systemic lupus erythematosus (SLE) – immune‑complex vasculitis producing palpable purpura.
• Rheumatoid arthritis and other connective‑tissue diseases – rheumatoid vasculitis.
• Infections – hepatitis B or C, HIV, streptococcal infections, bacterial endocarditis.
• Medications – antibiotics (e.g., penicillins, cephalosporins), allopurinol, thiazide diuretics, biologics.
• Malignancies – especially hematologic cancers such as lymphoma or leukemia.

Associated Symptoms

The skin findings rarely occur in isolation. Common accompanying manifestations depend on the underlying cause but may include:

• Fever or chills
• Joint pain or swelling (arthralgia/arthritis)
• Muscle aches (myalgia)
• Abdominal pain, nausea, or gastrointestinal bleeding (especially with IgA vasculitis)
• Renal involvement – hematuria, proteinuria, or reduced kidney function
• Respiratory symptoms – cough, shortness of breath, hemoptysis (seen in GPA, MPA)
• Nerve involvement – peripheral neuropathy, tingling, or burning sensations
• General fatigue and weight loss

When systemic symptoms are present, the disease is more likely to be a form of systemic vasculitis rather than an isolated cutaneous process.

When to See a Doctor

Any new or rapidly changing rash that looks like bruising, red or purple spots, or ulceration should prompt a medical evaluation, especially when any of the following are present:

• Lesions are painful, tender, or rapidly spreading.
• Accompanied by fever, night sweats, or unexplained weight loss.
• Joint swelling, abdominal pain, or coughing/shortness of breath develop.
• Kidney signs (blood in urine, swelling of ankles/feet).
• The rash appears after starting a new medication, after an infection, or following a recent vaccination.
• You have a known autoimmune disease (e.g., lupus, rheumatoid arthritis) and notice new skin changes.

Diagnosis

Diagnosing vasculitic skin lesions involves a stepwise approach that combines clinical assessment, laboratory studies, imaging, and, most importantly, a skin biopsy.

1. Clinical evaluation

• Detailed history – timing, triggers, medications, recent infections, systemic symptoms.
• Physical examination – description of lesion morphology (palpable purpura, petechiae, vesicles, nodules, ulcerations), distribution (lower extremities are classic), and presence of livedo reticularis.

2. Laboratory tests

• Complete blood count (CBC) – anemia, leukocytosis, eosinophilia.
• Inflammatory markers – ESR & CRP.
• Renal panel – serum creatinine, BUN, urinalysis for hematuria/proteinuria.
• Autoantibodies – ANCA (c‑ANCA, p‑ANCA), ANA, anti‑dsDNA, rheumatoid factor, complement levels (C3, C4).
• Infectious work‑up – hepatitis B/C serologies, HIV, throat cultures, blood cultures if endocarditis is suspected.
• Serum IgA level – useful in IgA vasculitis.

3. Skin biopsy

Biopsy of a fresh (<24‑48 h) lesion is the gold standard. A punch or incisional specimen is examined with routine hematoxylin‑eosin staining and, when needed, immunofluorescence for IgA, C3, or fibrin deposition. Histology distinguishes:

• Leukocytoclastic vasculitis (neutrophilic debris, fibrinoid necrosis).
• Immune‑complex deposition (IgA, IgG, C3).
• Granulomatous inflammation (suggesting GPA or EGPA).

4. Imaging (if systemic involvement suspected)

• Chest X‑ray or CT scan for pulmonary infiltrates or nodules.
• Duplex ultrasound of affected limbs if large‑vessel involvement is a concern.

Treatment Options

Treatment is individualized based on the severity of skin disease, presence of systemic organ involvement, and the underlying cause.

1. General measures

• Discontinue any suspected offending medication (often the first step).
• Rest the affected limbs and elevate them to reduce swelling.
• Cool compresses (not ice) to soothe painful lesions.
• Good skin hygiene – gentle cleansing, avoiding friction.

2. Pharmacologic therapy

• Topical corticosteroids (e.g., clobetasol 0.05%) for limited, mild lesions.
• Systemic corticosteroids – Prednisone 0.5–1 mg/kg/day for moderate‑to‑severe disease or when systemic involvement exists. Tapered over weeks to months.
• Immunosuppressive agents (reserved for refractory or systemic vasculitis):
  • Azathioprine, Mycophenolate mofetil, or Methotrexate.
  • Cyclophosphamide for life‑threatening organ involvement.
  • Rituximab (anti‑CD20) for ANCA‑associated vasculitis.
• Colchicine – useful in IgA vasculitis and leukocytoclastic vasculitis with limited lesions.
• Plasmapheresis – considered in severe renal or pulmonary vasculitis.
• Antibiotics/antivirals when an infectious trigger is identified (e.g., hepatitis C antiviral therapy).

3. Supportive care

• Pain control – acetaminophen or short‑course NSAIDs (if renal function permits).
• Compression stockings for lower‑leg purpura to improve venous return.
• Wound care for ulcerated lesions – non‑adherent dressings, infection surveillance.
• Vaccinations – influenza and pneumococcal vaccines for patients on long‑term immunosuppression.

Prevention Tips

While not all vasculitic skin lesions are preventable, risk reduction is possible:

• Medication awareness: Inform every prescriber of past drug reactions; keep a list of allergies.
• Infection control: Practice hand hygiene, stay current on vaccinations, and seek prompt treatment for bacterial infections.
• Control chronic diseases: Optimal management of diabetes, hypertension, and autoimmune disorders reduces vascular injury.
• Avoid smoking: Tobacco worsens vasculitis outcomes and impairs wound healing.
• Regular follow‑up: Patients with known systemic vasculitis should have scheduled labs and clinic visits to detect flares early.

Emergency Warning Signs

Key Take‑aways

Vasculitic skin lesions are a visible sign of blood‑vessel inflammation that may be isolated to the skin or a clue to a systemic disease. Prompt recognition, thorough evaluation—including a skin biopsy—and targeted treatment can prevent serious complications such as organ loss or limb ischemia. When in doubt, especially if systemic symptoms arise, contact a healthcare professional without delay.

---

References: Mayo Clinic. “Vasculitis.”; CDC. “Henoch‑Schönlein Purpura.”; NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases. “Vasculitis.”; Cleveland Clinic. “Cutaneous Vasculitis.”; UpToDate. “Diagnosis and Management of Cutaneous Small‑Vessel Vasculitis.”; WHO. “Guidelines for the Management of Autoimmune Diseases.”

```